These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25042873)

  • 21. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
    Mori T; Crandall CJ; Ganz DA
    Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone Loss After Denosumab: Only Partial Protection with Zoledronate.
    Reid IR; Horne AM; Mihov B; Gamble GD
    Calcif Tissue Int; 2017 Oct; 101(4):371-374. PubMed ID: 28500448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on "Variability of denosumab densitometric response in postmenopausal osteoporosis".
    Torrente-Segarra V; Roig-Vilaseca D
    Rheumatol Int; 2018 Jun; 38(6):1161-1162. PubMed ID: 29546636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis.
    Gu HF; Gu LJ; Wu Y; Zhao XH; Zhang Q; Xu ZR; Yang YM
    Medicine (Baltimore); 2015 Nov; 94(44):e1674. PubMed ID: 26554766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
    Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
    Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab.
    Catalano A; Gaudio A; Morabito N; Basile G; Agostino RM; Xourafa A; Atteritano M; Morini E; Natale G; Lasco A
    J Endocrinol Invest; 2017 Aug; 40(8):851-857. PubMed ID: 28332172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
    Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Denosumab for cancer-related bone loss.
    Dell'Aquila E; Armento G; Iuliani M; Simonetti S; D'Onofrio L; Zeppola T; Madaudo C; Russano M; Citarella F; Ribelli G; Pantano F; Vincenzi B; Tonini G; Santini D
    Expert Opin Biol Ther; 2020 Nov; 20(11):1261-1274. PubMed ID: 32835531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug holidays in women treated for postmenopausal osteoporosis.
    McClung MR
    Menopause; 2018 Oct; 25(10):1152-1154. PubMed ID: 30044265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.
    Dempster DW; Brown JP; Fahrleitner-Pammer A; Kendler D; Rizzo S; Valter I; Wagman RB; Yin X; Yue SV; Boivin G
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2498-2509. PubMed ID: 29672714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Suzuki T; Nakamura Y; Tanaka M; Kamimura M; Ikegami S; Uchiyama S; Kato H
    Mod Rheumatol; 2018 Mar; 28(2):376-379. PubMed ID: 28397581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab for Reducing Risk of Fractures in Postmenopausal Women.
    Song P; Zehtabchi S
    Am Fam Physician; 2019 May; 99(9):Online. PubMed ID: 31038897
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
    Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
    Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmenopausal Osteoporosis: A Clinical Review.
    Watts NB
    J Womens Health (Larchmt); 2018 Sep; 27(9):1093-1096. PubMed ID: 29583083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
    Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H; Taguchi A
    Osteoporos Int; 2017 Feb; 28(2):559-566. PubMed ID: 27650642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.
    Zheng J; van Schaick E; Wu LS; Jacqmin P; Perez Ruixo JJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):333-47. PubMed ID: 26123919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.